top
Search terms
Results 1 - 10 of 14 - ordered by :
Pages: 1 2
Ehjournal

Controversy only exists as to whether LDL cholesterol target levels or risk-adjusted dosing should be used in their management,5 with the former advocated by the European Society of Cardiology and ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/02/2015 Item size : 212610 bytes
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast The management and, as a consequence, the outcome of acute coronary syndromes or ACS have improved impressively over the last ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/04/2016 Item size : 257926 bytes
Ehjournal

The Framingham study and numerous cohorts thereafter subsequently confirmed the prognostic value of cholesterol and in particular LDL-cholesterol, and the 4S Trial2 eventually proved the cholesterol ...

European Heart Journal, Issue @ A Glance, Thomas F. Lüscher

Date : 14/10/2016 Item size : 197432 bytes
Ehjournal

In his notes he wrote: I found no material disease of the heart, except that the coronary arteries were thickened2 Rudolf Virchow was the first to recognize the inflammatory nature of atherosclerosis ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/03/2015 Item size : 221872 bytes
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Elevated levels of LDL-cholesterol are determined mainly genetically1 and are the most important risk factor for atherosclerosis in ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/05/2016
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Prevention is better that cure As Niccolo Machiavelli already pointed out in his seminal work Il Principe in 1513, any disease is ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 14/05/2015
Ehjournal

Furthermore, although statins are able to reduce LDL plasma levels and cardiovascular events successfully, there is considerable remaining risk. [...]novel approaches to lower LDL levels further are ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/01/2015
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast The field of percutaneous coronary intervention (PCI) remains extremely active and fruitful, with major advances involving ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/01/2016
Ehjournal

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial See page 3248 for the editorial comment on ...

European Heart Journal, Coronary artery disease, Jean-Claude Tardif, Christie M. Ballantyne, Philip Barter, Jean-Louis Dasseux, Zahi A. Fayad, Marie-Claude Guertin, John J. P. Kastelein, Constance ...

Date : 07/12/2014
Ehjournal

Furthermore, the EMPA-REG OUTCOME trial using the novel antihyperglycaemic agent, empagliflozin,8 a selective sodiumglucose co- transporter inhibitor, significantly reduced cardiovascular mortality; ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 07/02/2016